Phase 2 Dose Finding sPIF in Patients With High Panel Reactive Antibodies

Inclusion Criteria: * Outpatient male and females 18-75 years old * Able and willing to give written informed consent and comply with the requirements of the study protocol * Calculated panel reactive antibody (cPRA) \>30% and \<60% with a threshold using mean fluorescent intensity (MFI) of 3,000 or standard fluorescence intensity (SFI) of 60,000 over six months. * Women who are of childbearing potential must have a negative serum pregnancy test prior to being enrolled in the study and agree to use effective method of contraception throughout the 84-day study. * Patients on kidney dialysis 3.3 Exclusion Criteria * Patients not capable of following through the treatment for various reasons as determined by treating physicians * Pregnant females * Requiring blood transfusions * Have an active infection * Infection with hepatitis C virus (HCV) or hepatitis B virus(HBV) or human immunodeficiency virus (HIV), lack of documentation of treatment of a positive PPD, baseline leukopenia, white blood cell count (WBC) \<4.0, thrombocytopenia (platelet count \<100,000/mm) or difficult to treat anemia, a hematocrit chronically \<25% on intravenous iron and EPO (erythropoietin) therapy * Active cancer within 5 years * Significant cardiac or pulmonary disease (including obstructive pulmonary disease)